產(chǎn)品訂購(gòu)信息：
英文名稱  Anti-STIL 

中文名稱   中斷位點(diǎn)蛋白STIL抗體說(shuō)明書(shū) 

別    名  MCPH7; SCL interrupting locus protein; SCL-interrupting locus protein; SCL/TAL1 interrupting locus; SIL; STIL; STIL_HUMAN; TAL 1 interrupting locus protein; TAL-1-interrupting locus protein.

濃    度   1mg/1ml

規(guī) 格  0.2ml/200μg

抗體來(lái)源   Rabbit

克隆類型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Cow, Rabbit 

產(chǎn)品類型   一抗  

研究領(lǐng)域     細(xì)胞生物 免疫學(xué) 神經(jīng)生物學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 干細(xì)胞 細(xì)胞周期蛋白 細(xì)胞分化

蛋白分子量  predicted molecular weight: 143kDa

性    狀   Lyophilized or Liquid

免 疫 原 KLH conjugated synthetic peptide derived from human STIL 

亞    型   IgG

純化方法   affinity purified by Protein A

儲(chǔ) 存 液   Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4

中斷位點(diǎn)蛋白STIL抗體說(shuō)明書(shū) 產(chǎn)品應(yīng)用    WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1:20-100 IF=1:50-200

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 TAL1 disruption at 1p32, a common rearrangement in the T-cell acute lymphoblastic leukemia, usually results in the formation of a SCL interrupting locus (SIL)-TAL1 fusion product. SIL is an immediate early gene whose expression is associated with cell proliferation. The Sil protein exhibits ubiquitous expression in hematopoietic cell lines and tissues. However, Sil protein levels remain tightly regulated during the cell cycle, achieving peak levels in mitosis and diminishing on transition to G1 phase. Overexpression of Sil in primary adenocarcinomas predicts metastatic spread, especially in lung tumors with increased mitotic activity.

Function : Immediate-early gene. Plays an important role in embryonic development as well as in cellular growth and proliferation; its long-term silencing affects cell survival and cell cycle distribution as well as decreases CDK1 activity correlated with reduced phosphorylation of CDK1. Plays a role as a positive regulator of the sonic hedgehog pathway, acting downstream of PTCH1.

Subunit : Interacts with PIN1 via its WW domain. This interaction is dependent on STIL mitotic phosphorylation (By similarity).

Subcellular Location : Cytoplasm, cytosol.

Tissue Specificity : Expressed in all hematopoietic tissues and cell lines. Highly expressed in a variety of tumors characterized by increased mitotic activity with highest expression in lung cancer.

Post-translational modifications : Phosphorylated following the activation of the mitotic checkpoint.

DISEASE : Note=A chromosomal aberration involving STIL may be a cause of some T-cell acute lymphoblastic leukemias (T-ALL). A deletion at 1p32 between STIL and TAL1 genes leads to STIL/TAL1 fusion mRNA with STIL exon 1 slicing to TAL1 exon 3. As both STIL exon 1 and TAL1 exon 3 are 5'-untranslated exons, STIL/TAL1 fusion mRNA predicts a full length TAL1 protein under the control of the STIL promoter, leading to inappropriate TAL1 expression. In childhood T-cell malignancies (T-ALL), a type of defect such as STIL/TAL1 fusion is associated with a good prognosis. In cultured lymphocytes from healthy adults, STIL/TAL1 fusion mRNA may be detected after 7 days of culture.

Defects in STIL are the cause of microcephaly primary type 7 (MCPH7) [MIM:612703]. Microcephaly is defined as a head circumference more than 3 standard deviations below the age-related mean. Brain weight is markedly reduced and the cerebral cortex is disproportionately small. Despite this marked reduction in size, the gyral pattern is relatively well preserved, with no major abnormality in cortical architecture. Primary microcephaly is further defined by the absence of other syndromic features or significant neurological deficits.

Database links : UniProtKB/Swiss-Prot: Q15468.2

改良克氏雙糖鐵培養(yǎng)基250g生化培養(yǎng)基，用于小腸耶爾森氏菌的生化反應(yīng)篩選

改良MSRV培養(yǎng)基 MSRV Medium，Modified 用于沙門氏的分離培養(yǎng)(MERCK方法)

小牛浸膏粉 Beef extract powder 250克 BR

含糖牛肉湯培養(yǎng)基250g/瓶用于乳酸菌培養(yǎng)和鑒別incubationmedia含糖牛肉湯培養(yǎng)基250g/瓶用于乳酸菌培養(yǎng)和鑒別

Tergitol-7瓊脂 250g 用于大腸菌群的鑒定(NMKL)

改良磷酸鹽緩沖液PSB250g用于小腸耶爾森氏菌增菌培養(yǎng)

鹽增菌液(SF) Selenite Enrichment Medium 用于增殖標(biāo)本中的沙門氏菌

脫氫膽酸 Sodium dehydrocholate 25克 BR，98%

改良番茄汁瓊脂培養(yǎng)基250g/瓶用于乳酸菌總數(shù)測(cè)定incubationmedia改良番茄汁瓊脂培養(yǎng)基250g/瓶用于乳酸菌總數(shù)測(cè)定

AcetateAgar

頭孢菌素紙片(30ug/片)用于空腸彎曲菌藥敏試驗(yàn)。

mTSB肉湯 mTSB Broth With Novobiocin 用于0157選擇性增菌(ISO方法)

UBA　培養(yǎng)基 UBA　Medium 250 用于啤酒中厭氧菌檢測(cè)

堿性蛋白胨水(APW)250g/瓶用于弧菌選擇性增菌incubationmedia堿性蛋白胨水(APW)250g/瓶用于弧菌選擇性增菌

RVBroth

CL-0146LTEP-a-2(人)5×106cells/瓶×2

IL27 Others Human 人 IL27 / Ierleukin-27 CHO細(xì)胞裂解液 (陽(yáng)性對(duì)照)

人尿道上皮細(xì)胞裂解物HUCL

長(zhǎng)白山豬胚胎皮膚成纖維樣細(xì)胞;201184 *癌細(xì)胞，CFPAC-1細(xì)胞 Ranca細(xì)胞，小鼠細(xì)胞

SV40T轉(zhuǎn)化的人胚腎細(xì)胞;293T

HA Others H1N1 甲型 H1N1 (A/Puerto Rico/8/1934) 血凝素HA1 (Hemagglutinin) 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)

中斷位點(diǎn)蛋白STIL抗體說(shuō)明書(shū)CL-0144LoVo(人細(xì)胞)5×106cells/瓶×2

GPT2 Others Rat 大鼠 GPT2 桿狀病毒-昆蟲(chóng)細(xì)胞裂解液 (陽(yáng)性對(duì)照)

人腎系膜細(xì)胞裂解物HRMCL

SK-OV-3[SKOV-3]細(xì)胞，人細(xì)胞 人上皮細(xì)胞,HBE細(xì)胞 腦膜細(xì)胞Many types of cells包裝：5 × 105次方(1ml)

兔角膜前基質(zhì)層成纖維細(xì)胞;RCFBF

TEK Others Human 人 Tie2 / CD202b 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)

抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：

1. 中斷位點(diǎn)蛋白STIL抗體說(shuō)明書(shū) 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；

2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來(lái)篩選最適條件；

3.用NHSB量過(guò)量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；

4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等；

5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性；

6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價(jià)結(jié)合；

7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對(duì)生物素化抗體與親和素的結(jié)合產(chǎn)生競(jìng)爭(zhēng)作用；

8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。

抗體的鑒定：

1）中斷位點(diǎn)蛋白STIL抗體說(shuō)明書(shū) 抗體的效價(jià)鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來(lái)鑒定。

2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力?？贵w的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來(lái)表示。交叉反應(yīng)率可用競(jìng)爭(zhēng)抑制試驗(yàn)測(cè)定。以不同濃度抗原和近似抗原分別做競(jìng)爭(zhēng)抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。 

如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無(wú)窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。

3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫(kù)侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測(cè)定對(duì)抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。